apixaban

First-line for stroke prevention in non-valvular atrial fibrillation per ESC 2024 and AHA/ACC 2023. DOACs are preferred over warfarin in most patients. The ARISTOTLE trial (over 18,000 patients) demonstrated a 21 % reduction in stroke or systemic embolism, a 31 % reduction in major bleeding, and an 11 % reduction in all-cause mortality versus warfarin. Standard dose 5 mg twice daily. The 2.5 mg twice-daily dose applies to patients with at least two of: age ≥ 80, body weight ≤ 60 kg, or serum creatinine ≥ 133 µmol/L.

Standard dose 5 mg twice daily. Reduce to 2.5 mg twice daily if any two of three criteria are met: age ≥ 80 years, body weight ≤ 60 kg, serum creatinine ≥ 1.5 mg/dL. Clinical data are limited at eGFR < 15 mL/min/1.73 m².

First-line treatment for deep vein thrombosis and pulmonary embolism in outpatients without contraindications per CHEST 2021 and ESC 2019. Loading dose 10 mg twice daily for 7 days, then 5 mg twice daily for up to 6 months. For long-term secondary prevention beyond 6 months, 2.5 mg twice daily is acceptable. DOACs are not used in high-risk antiphospholipid syndrome (triple positivity) — warfarin remains standard there.

After the COVID-19 pandemic some patients took up the habit of taking apixaban, rivaroxaban, and other DOACs at the first symptoms of an upper respiratory infection «for blood thinning and thrombosis prevention». International guidelines do not support this. Outpatient viral URI is self-limiting, clinically meaningful thromboembolism risk is not elevated, and major bleeding risk on apixaban remains the same. WHO, NICE, ASH, and ISTH do not mention anticoagulants for outpatient URI. Evidence-based management is rest, hydration, symptomatic measures; antivirals (oseltamivir, nirmatrelvir/ritonavir) are reserved for confirmed influenza or COVID-19 in high-risk patients.

For mild and moderate outpatient COVID-19, apixaban is not prescribed for thrombosis prophylaxis. Apixaban itself was tested in the ACTIV-4B RCT (Connors et al., JAMA 2021): 657 symptomatic outpatients were randomised to aspirin 81 mg, prophylactic apixaban 2.5 mg twice daily, therapeutic apixaban 5 mg twice daily, or placebo. The trial was stopped early for futility at very low event rates: anticoagulants did not reduce hospitalisations, thromboses, or mortality, while therapeutic-dose apixaban produced a 6.9 % absolute increase in bleeding events compared with placebo. The updated ASH 2024 living guideline (Blood Advances) issued a conditional recommendation against routine post-discharge thromboprophylaxis in COVID-19; the WHO Therapeutics Living Guideline and NICE NG191 do not support routine DOAC use in outpatients. Non-severe hospitalised patients benefit from low-molecular-weight heparin under supervision, not oral DOACs. Self-administered Eliquis «just in case» for COVID-19 has no evidence base.

Direct oral anticoagulants are contraindicated in patients with mechanical heart valves. The RE-ALIGN trial with dabigatran was stopped early due to increased valve thrombosis and bleeding compared with warfarin. No analogous RCT exists for apixaban, and the class effect is extrapolated. In these patients, warfarin remains first-line with INR target 2.5–3.5 depending on valve position and generation.